TY - JOUR
T1 - Endogenous fecal losses of calcium compromise calcium balance in pancreatic-insufficient girls with cystic fibrosis
AU - Schulze, Kerry J.
AU - O'Brien, Kimberly O.
AU - Germain-Lee, Emily L.
AU - Baer, David J.
AU - Leonard, Amanda L.R.
AU - Rosenstein, Beryl J.
PY - 2003/12
Y1 - 2003/12
N2 - Objective: Bone mineral density is compromised in individuals with cystic fibrosis (CF); calcium is the major bone mineral. This study examined the impact of endogenous fecal calcium (Vendo) losses on calcium balance in girls with CF. Study design: Vendo was measured in 12 girls with CF (aged 7-18 years): 7 younger, premenarcheal girls with compromised nutritional status: and 5 older, postmenarcheal girls with adequate nutritional status. Vendo was measured as the amount of intravenously administered 42Ca, a calcium stable isotope, in stool relative to urine over 6 days. Vendo was compared between pre- and postmenarcheal girls by Student's t test. Actual calcium balance [absorbed calcium-(urinary calcium (Vu) + Vendo)] was compared with estimated balance (assuming Vendo = 1.6 mg/kg/day calcium) by paired t test. Results: Vendo was 99.3 ± 42.3 mg/day. By body weight, Vendo was highest among premenarcheal girls (3.37 ± 1.09 mg/kg/day), resulting in excess losses (>1.6 mg/kg/day) of 55.0 ± 45. 7 mg/day. Over 1 year, this represents 20.1 ± 16.7 g of unattained bone calcium or 6.7 ± 4.2% of die bone calcium content of these girls. Conclusions: Vendo is a significant source of calcium loss in individuals with CF and may limit calcium availability for bone mineral deposition.
AB - Objective: Bone mineral density is compromised in individuals with cystic fibrosis (CF); calcium is the major bone mineral. This study examined the impact of endogenous fecal calcium (Vendo) losses on calcium balance in girls with CF. Study design: Vendo was measured in 12 girls with CF (aged 7-18 years): 7 younger, premenarcheal girls with compromised nutritional status: and 5 older, postmenarcheal girls with adequate nutritional status. Vendo was measured as the amount of intravenously administered 42Ca, a calcium stable isotope, in stool relative to urine over 6 days. Vendo was compared between pre- and postmenarcheal girls by Student's t test. Actual calcium balance [absorbed calcium-(urinary calcium (Vu) + Vendo)] was compared with estimated balance (assuming Vendo = 1.6 mg/kg/day calcium) by paired t test. Results: Vendo was 99.3 ± 42.3 mg/day. By body weight, Vendo was highest among premenarcheal girls (3.37 ± 1.09 mg/kg/day), resulting in excess losses (>1.6 mg/kg/day) of 55.0 ± 45. 7 mg/day. Over 1 year, this represents 20.1 ± 16.7 g of unattained bone calcium or 6.7 ± 4.2% of die bone calcium content of these girls. Conclusions: Vendo is a significant source of calcium loss in individuals with CF and may limit calcium availability for bone mineral deposition.
UR - http://www.scopus.com/inward/record.url?scp=0344233240&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0344233240&partnerID=8YFLogxK
U2 - 10.1067/S0022-3476(03)00539-0
DO - 10.1067/S0022-3476(03)00539-0
M3 - Article
C2 - 14657825
AN - SCOPUS:0344233240
SN - 0022-3476
VL - 143
SP - 765
EP - 771
JO - Journal of Pediatrics
JF - Journal of Pediatrics
IS - 6
ER -